Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis

G Yosipovitch, M Reaney, V Mastey, L Eckert, A Abbé, L Nelson, M Clark, N Williams, Z Chen, M Ardeleanu, B Akinlade, N M H Graham, G Pirozzi, H Staudinger, S Plaum, A Radin, A Gadkari, G Yosipovitch, M Reaney, V Mastey, L Eckert, A Abbé, L Nelson, M Clark, N Williams, Z Chen, M Ardeleanu, B Akinlade, N M H Graham, G Pirozzi, H Staudinger, S Plaum, A Radin, A Gadkari

Abstract

Background: Moderate-to-severe atopic dermatitis (AD) is a chronic disease characterized by intense, persistent and debilitating itch, resulting in sleep deprivation, signs of anxiety and depression, impaired quality of life and reduced productivity. The Peak Pruritus Numerical Rating Scale (NRS) was developed and validated as a single-item, patient-reported outcome (PRO) of itch severity.

Objectives: To describe the content validity and psychometric assessment (test-retest reliability, construct validity, known-groups validity, sensitivity to change) of the Peak Pruritus NRS, and to derive empirically a responder definition to identify adults with a meaningful change in itch.

Methods: Content validity was assessed through in-depth patient interviews. Psychometric assessments used data from phase IIb and phase III dupilumab clinical trials and included test-retest reliability, construct validity, known-groups validity and sensitivity to change in patients with moderate-to-severe AD.

Results: Interview participants indicated that the Peak Pruritus NRS was a relevant, clear and comprehensive assessment of itch severity. Peak Pruritus NRS scores showed large, positive correlations with existing PRO measures of itch, and weak or moderate correlations with clinician-reported measures assessing objective signs of AD. Peak Pruritus NRS score improvements were highly correlated with improvements in other itch PROs, and moderately correlated with improvements in clinician-reported measures assessing objective signs of AD. The most appropriate threshold for defining a clinically relevant, within-person response was ≥ 2-4-point change in the Peak Pruritus NRS.

Conclusions: The Peak Pruritus NRS is a well-defined, reliable, sensitive and valid scale for evaluating worst itch intensity in adults with moderate-to-severe AD.

© 2019 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.

References

    1. Bieber T. Atopic dermatitis. N Engl J Med 2008; 358:1483–94.
    1. Murray CJ, Richards MA, Newton JN et al UK health performance: findings of the Global Burden of Disease Study 2010. Lancet 2013; 381:997–1020.
    1. Wittkowski A, Richards HL, Griffiths CE, Main CJ. The impact of psychological and clinical factors on quality of life in individuals with atopic dermatitis. J Psychosom Res 2004; 57:195–200.
    1. Murota H, Takahashi A, Nishioka M et al Showering reduces atopic dermatitis in elementary school students. Eur J Dermatol 2010; 20:410–11.
    1. Simpson EL, Bieber T, Eckert L et al Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol 2016; 74:491–8.
    1. Sutton EL. Psychiatric disorders and sleep issues. Med Clin North Am 2014; 98:1123–43.
    1. Zachariae R, Zachariae C, Ibsen HH et al Psychological symptoms and quality of life of dermatology outpatients and hospitalized dermatology patients. Acta Derm Venereol 2004; 84:205–12.
    1. O'Neil JL, Chan YH, Rapp SR, Yosipovitch G. Differences in itch characteristics between psoriasis and atopic dermatitis patients: results of a web‐based questionnaire. Acta Derm Venereol 2011; 91:537–40.
    1. Ständer S, Augustin M, Reich C et al Pruritus assessment in clinical trials: consensus recommendations from the International Forum for the Study of Itch (IFSI) Special Interest Group Scoring Itch in Clinical Trials. Acta Derm Venereol 2013; 93:509–14.
    1. Harmonising Outcome Measures for Eczema (HOME) . HOME Meetings and Progress on COS. Available at: (last accessed 18 March 2019).
    1. Chalmers JR, Simpson E, Apfelbacker CJ et al Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). Br J Dermatol 2016; 175:69–79.
    1. Wyrwich KW, Norquist JM, Lenderking WR, Acaster S. Methods for interpreting change over time in patient‐reported outcome measures. Qual Life Res 2013; 22:475–83.
    1. McLeod LD, Coon CD, Martin SA et al Interpreting patient‐reported outcome results: US FDA guidance and emerging methods. Expert Rev Pharmacoecon Outcomes Res 2011; 11:163–9.
    1. Yosipovitch G, Reaney M, Mastey V et al. Validation of the peak pruritus numerical rating scale: results from clinical studies of dupilumab in adult patients with moderate‐to‐severe atopic dermatitis. Presented at the 75th Annual Meeting of the American Academy of Dermatology, Orlando, FL, U.S.A., 20–24 March 2017.
    1. Haydek CG, Love E, Mollanazar NK et al Validation and banding of the ItchyQuant: a self‐report itch severity scale. J Invest Dermatol 2017; 137:57–61.
    1. Kimball AB, Naegeli AN, Edson‐Heredia E et al Psychometric properties of the Itch Numeric Rating Scale in patients with moderate‐to‐severe plaque psoriasis. Br J Dermatol 2016; 175:157–62.
    1. Naegeli AN, Flood E, Tucker J et al The Worst Itch Numeric Rating Scale for patients with moderate to severe plaque psoriasis or psoriatic arthritis. Int J Dermatol 2015; 54:715–22.
    1. US Food and Drug Administration . Patient‐reported outcome measures: use in medical product development to support labeling claims. Available at: (last accessed 18 March 2019).
    1. Thaçi D, Simpson EL, Beck LA et al Efficacy and safety of dupilumab in adults with moderate‐to‐severe atopic dermatitis inadequately controlled by topical treatments: a randomized, placebo‐controlled, dose‐ranging phase 2b trial. Lancet 2016; 387:40–52.
    1. Simpson EL, Bieber T, Guttman‐Yassky E et al Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016; 375:2335–48.
    1. Kaufmann R, Bieber T, Helgesen AL et al Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis: a randomized trial. Allergy 2006; 61:375–81.
    1. Phan NQ, Blome C, Fritz F et al Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol 2012; 92:502–7.
    1. Rehal B, Armstrong A. Health outcome measures in atopic dermatitis: a systematic review of trends in disease severity and quality‐of‐life instruments 1985–2010. PLOS ONE 2011; 6:e17520.
    1. Hanifin JM, Thurston M, Omoto M et al The Eczema Area and Severity Index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group . Exp Dermatol 2001; 10:11–18.
    1. Chalmers JR, Schmitt J, Apfelbacher C et al Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME). Br J Dermatol 2014; 171:1318–25.
    1. Barbier N, Paul C, Luger T et al Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. Br J Dermatol 2004; 150:96–102.
    1. McGraw K, Wong SP. Forming inferences about some intraclass correlation coefficients. Psychol Methods 1996; 1:30–46.
    1. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull 1979; 86:420–8.
    1. Nunnally JC, Bernstein IH. Psychometric Theory, 3rd edn New York, NY: McGraw‐Hill Inc, 1994.
    1. Cohen J. A power primer. Psychol Bull 1992; 112:155–9.
    1. Coon CD, Cappelleri JC. Interpreting change in scores on patient‐reported outcome instruments. Ther Innov Regul Sci 2016; 50:22–9.
    1. Terwee CB, Bot SD, de Boer MR et al Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol 2007; 60:34–42.
    1. Elman S, Hynan LS, Gabriel V et al The 5‐D itch scale: a new measure of pruritus. Br J Dermatol 2010; 162:587–93.
    1. Reich A, Heisig M, Phan NQ et al Visual analogue scale: evaluation of the instrument for the assessment of pruritus. Acta Derm Venereol 2012; 92:497–501.
    1. Ständer S, Blome C, Anastasiadou Z et al Dynamic pruritus score: evaluation of the validity and reliability of a new instrument to assess the course of pruritus. Acta Derm Venereol 2017; 97:230–4.
    1. Reich A, Riepe C, Anastasiadou Z et al Itch assessment with visual analog scale and numerical rating scale: determination of minimal clinically important difference in chronic itch. Acta Derm Venereol 2016; 96:978–80.
    1. Wright A, Hannon J, Hegedus EJ, Kavchak AE. Clinimetrics corner: a closer look at the minimal clinically important difference (MCID). J Man Manip Ther 2012; 20:160–6.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel